Evidence map›Paper›PMID 37100172›Full record

ArticleJournal of lipid research2023

Low concentrations of medium-sized HDL particles predict incident CVD in chronic kidney disease patients.

Baohai Shao, Farsad Afshinnia, Anna V Mathew, Graziella E Ronsein, Carissa Thornock, Angela D Irwin, Mayank Kansal, Panduranga S Rao, Mirela Dobre, Sadeer Al-Kindi and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of lipid research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Baohai ShaoDepartment of Medicine, UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA. Electronic address: bhshao@uw.edu.
Farsad AfshinniaDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Anna V MathewDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Graziella E RonseinDepartment of Medicine, UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
Carissa ThornockDepartment of Medicine, UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
Angela D IrwinDepartment of Medicine, UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
Mayank KansalDepartment of Cardiology, University of Illinois at Chicago, Chicago, IL, USA.
Panduranga S RaoDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Mirela DobreDivision of Nephrology and Hypertension, Case Western Reserve University, Cleveland, OH, USA.
Sadeer Al-KindiDivision of Nephrology and Hypertension, Case Western Reserve University, Cleveland, OH, USA.
Matthew R WeirDivision of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Alan GoDepartment of Health System Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
Jiang HeDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Jing ChenDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA; Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA.
Harold FeldmanDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Karin E BornfeldtDepartment of Medicine, UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
Subramaniam PennathurDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA. Electronic address: spennath@med.umich.edu.
Michigan Kidney Translational Core CPROBE Investigator Group and the CRIC Study Investigators
University of Washington · USUniversity of Michigan · USCase Western Reserve University · USTulane University · USKaiser Permanente · USUniversity of Illinois Chicago · USUniversity of Maryland, Baltimore · USUniversity of Pennsylvania · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Ning Liu · 2016 to 2026
$25.3M
Project 3 - HDL Structure/Function in LCAT Deficient HumansP01HL128203 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI W Sean Davidson · 2016 to 2026
$25.1M
Role of Serum Amyloid A in Diabetic Vascular DiseaseP01HL092969 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E. · 2008 to 2019
$23.5M
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kanakadurga Singer · 2010 to 2026
$20.3M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI ONUKWUGHA, EBERECHUKWU · 2002 to 2009
$20.2M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCRR NIH HHS M01 RR016500NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR029879NHLBI NIH HHS K08 HL130944NHLBI NIH HHS P01 HL092969NHLBI NIH HHS P01 HL128203NHLBI NIH HHS P01 HL151328NHLBI NIH HHS R01 HL108897NHLBI NIH HHS R01 HL112625NHLBI NIH HHS R01 HL149685NHLBI NIH HHS R01 HL161829NHLBI NIH HHS R35 HL150754NHLBI NIH HHS R56 HL156829NHLBI NIH HHS R56 HL159549NIDDK NIH HHS DP3 DK108209NIDDK NIH HHS K08 DK106523NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK081943NIDDK NIH HHS P30 DK089503NIDDK NIH HHS R01 DK119199NIDDK NIH HHS R03 DK121941NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U24 DK060990NIGMS NIH HHS P20 GM109036
6 · The paper itself

Abstract

Patients with chronic kidney disease (CKD) are at high risk for CVD. However, traditional CVD risk factors cannot completely explain the increased risk. Altered HDL proteome is linked with incident CVD in CKD patients, but it is unclear whether other HDL metrics are associated with incident CVD in this population. In the current study, we analyzed samples from two independent prospective case-control cohorts of CKD patients, the Clinical Phenotyping and Resource Biobank Core (CPROBE) and the Chronic Renal Insufficiency Cohort (CRIC). We measured HDL particle sizes and concentrations (HDL-P) by calibrated ion mobility analysis and HDL cholesterol efflux capacity (CEC) by cAMP-stimulated J774 macrophages in 92 subjects from the CPROBE cohort (46 CVD and 46 controls) and in 91 subjects from the CRIC cohort (34 CVD and 57 controls). We tested associations of HDL metrics with incident CVD using logistic regression analysis. No significant associations were found for HDL-C or HDL-CEC in either cohort. Total HDL-P was only negatively associated with incident CVD in the CRIC cohort in unadjusted analysis. Among the six sized HDL subspecies, only medium-sized HDL-P was significantly and negatively associated with incident CVD in both cohorts after adjusting for clinical confounders and lipid risk factors with odds ratios (per 1-SD) of 0.45 (0.22-0.93, P = 0.032) and 0.42 (0.20-0.87, P = 0.019) for CPROBE and CRIC cohorts, respectively. Our observations indicate that medium-sized HDL-P-but not other-sized HDL-P or total HDL-P, HDL-C, or HDL-CEC-may be a prognostic cardiovascular risk marker in CKD.

Indexed as

Cardiovascular DiseasesRenal Insufficiency, ChronicCholesterol, HDLHumansRisk FactorsCholesterol, HDLcardiovascular diseasecase-control studycholesterol efflux capacityCKDHDL-C levelsHDL particle concentrationhigh density lipoproteinincident CVDion mobility analysismedium HDL-P

Identifiers

PMID37100172
PMCPMC10323925
OpenAlexW4366825002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.